Brian Lian - 31 Jan 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
31 Jan 2024
Net transactions value
-$1,996,200
Form type
4
Filing time
31 Jan 2024, 20:39:53 UTC
Previous filing
30 Jan 2024
Next filing
08 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $104,550 +85,000 +3.8% $1.23* 2,349,882 31 Jan 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale $978,000 -40,000 -1.7% $24.45 2,309,882 31 Jan 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale $1,122,750 -45,000 -1.9% $24.95 2,264,882 31 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (right to buy) Options Exercise $0 -85,000 -86% $0.000000 14,148 31 Jan 2024 Common Stock 85,000 $1.23 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023.
F2 25% of the shares subject to the option vested on each one year anniversary of the grant date.